Author

A. M. Contino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Folgori· 2 shared S. Battella· 2 shared S. Capone· 2 shared A. C. Hayday· 1 shared A. Lahm· 1 shared A. Leuzzi· 1 shared A. Natalini· 1 shared A. Nicosia· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Folgori

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature.

A. Natalini, S. Simonetti, G. Favaretto, L. Lucantonio, G. Peruzzi, M. Munoz-Ruiz, G. Kelly, A. M. Contino, R. Sbrocchi, S. Battella, S. Capone, A. Folgori, A. Nicosia, A. Santoni, A. C. Hayday, F. Di Rosa

The study shows that a delayed vaccine boost at day 100 post-prime enhances CD8 T cell memory response compared to day 30, with a distinct molecular signature in splenic cells.

bioRxiv · Aug 4, 2022Immunology

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

A. Vitelli, S. Capone, A. Raggioli, M. Gentile, S. Battella, A. Lahm, A. Sommella, A. M. Contino, R. A. Urbanowicz, R. Scala, F. Barra, A. Leuzzi, E. Lilli, G. Miselli, A. Noto, , S. Colloca

This paper evaluates a gorilla adenovirus vaccine candidate for COVID-19, showing it is immunogenic in mice and macaques and supports its advancement to a Phase I clinical trial.

bioRxiv · Oct 22, 2020Immunology